Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?

Bouvard, 2009, WHO international agency for research on cancer monograph working group. A review of human carcinogens-Part B: biological agents, 10, 321 Ang, 2010, Human papillomavirus and survival of patients with oropharyngeal cancer, N Engl J Med, 363, 24, 10.1056/NEJMoa0912217 Fakhry, 2008, Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial, J Natl Cancer Inst, 100, 261, 10.1093/jnci/djn011 O’Sullivan, 2016, Development and validation of a staging system for HPV-related oropharyngeal cancer by the international collaboration on oropharyngeal cancer network for staging (ICON-S): a multicentre cohort study, Lancet Oncol, 17, 440, 10.1016/S1470-2045(15)00560-4 Markovic, 2012, Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma, Expert Rev Anticancer Ther, 12, 1149, 10.1586/era.12.91 Bonner, 2006, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N Engl J Med, 354, 567, 10.1056/NEJMoa053422 Licitra, 2006, High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma, J Clin Oncol, 24, 5630, 10.1200/JCO.2005.04.6136 Buglione, 2017, Subgroup analysis according to human papillomavirus status and tumor site of a randomized phase II trial comparing cetuximab and cisplatin combined with radiation therapy for locally advanced head and neck cancer, Int J Radiat Oncol Biol Phys, 97, 462, 10.1016/j.ijrobp.2016.10.011 Roesler, 2013, Failure of anti-EGFR therapy in p16-positive head and neck cancer, Lancet Oncol, 14, 436, 10.1016/S1470-2045(13)70400-5 Mirghani, 2014, Oropharyngeal cancers: relationship between epidermal growth factor receptor alterations and human papillomavirus status, Eur J Cancer, 50, 1100, 10.1016/j.ejca.2013.12.018 Keck, 2015, Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes, Clin Cancer Res, 21, 870, 10.1158/1078-0432.CCR-14-2481 Cancer Genome Atlas Network, 2015, Comprehensive genomic characterization of head and neck squamous cell carcinomas, Nature, 517, 576, 10.1038/nature14129 Hu, 2015, Human papillomavirus 16 oncoprotein regulates the translocation of b-catenin via the activation of epidermal growth factor receptor, Cancer, 121, 214, 10.1002/cncr.29039 Vermorken, 2013, Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial, Lancet Oncol, 14, 697, 10.1016/S1470-2045(13)70181-5 Machiels, 2015, Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial, Lancet Oncol, 16, 583, 10.1016/S1470-2045(15)70124-5 Ang KK, Zhang QE, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III–IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 2011:5500 [2011 ASCO annual meeting proceedings (post-meeting ed.), vol. 29, No 15_suppl (May 20 Supplement)]. Seiwert T, Fayette J, Cupissol D, et al. A randomized, openlabel, phase II study of afatinib (BIBW 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: final data. In: Presented at the multidisciplinary head and neck cancer symposium, Phoenix, AZ, January 26, 2012. Vermorken, 2014, Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial, Ann Oncol, 25, 801, 10.1093/annonc/mdt574 Rosenthal, 2016, J Clin Oncol, 34, 1300, 10.1200/JCO.2015.62.5970 Eisbruch, 2004, Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT?, Int J Radiat Oncol Biol Phys, 60, 1425, 10.1016/j.ijrobp.2004.05.050 Levendag, 2007, Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship, Radiother Oncol, 85, 64, 10.1016/j.radonc.2007.07.009 Feng, 2007, Intensity modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures, Int J Radiat Oncol Biol Phys, 68, 1289, 10.1016/j.ijrobp.2007.02.049 Ensley, 1984, Correlation between response to cis– platinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck, Cancer, 54, 811, 10.1002/1097-0142(19840901)54:5<811::AID-CNCR2820540508>3.0.CO;2-E Mirghani, 2015, Increased radiosensitivity of HPV-positive head and neck cancers: molecular basis and therapeutic perspectives, Cancer Treat Rev, 41, 844, 10.1016/j.ctrv.2015.10.001 Marur, 2016, E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx– ECOG-ACRIN cancer research group, J Clin Oncol, 10, 836 Chen, 2017, Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study, Lancet Oncol, 18, 803, 10.1016/S1470-2045(17)30246-2 http://www.clinicaltrial.gouv. Rainey, 2017, J Clin Oncol, 35, 6069, 10.1200/JCO.2017.35.15_suppl.6069 Villaflor, 2016, Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer, Ann Oncol, 27, 908, 10.1093/annonc/mdw051 Dawson, 2000, Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer, Int J Radiat Oncol Biol Phys, 46, 1117, 10.1016/S0360-3016(99)00550-7 Spencer, 2014, Eliminating radiotherapy to the contralateral retropharyngeal and high level II lymph nodes in head and neck squamous cell carcinoma is safe and improves quality of life, Cancer, 120, 3994, 10.1002/cncr.28938 O’Sullivan, 2013, Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis, J Clin Oncol, 31, 543, 10.1200/JCO.2012.44.0164 Machtay, 2008, Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis, J Clin Oncol, 26, 3582, 10.1200/JCO.2007.14.8841 Chera, 2015, Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma, Int J Radiat Oncol Biol Phys, 93, 976, 10.1016/j.ijrobp.2015.08.033 Lee, 2016, Strategy of using intratreatment hypoxia imaging to selectively and safely guide radiation dose de-escalation concurrent with chemotherapy for locoregionally advanced human papillomavirus-related oropharyngeal carcinoma, Int J Radiat Oncol Biol Phys, 96, 9, 10.1016/j.ijrobp.2016.04.027 Huang, 2015, Refining American joint committee on cancer/union for international cancer control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas, J Clin Oncol, 33, 836, 10.1200/JCO.2014.58.6412 Chen, 2013, Definitive radiation therapy without chemotherapy for human papillomavirus-positive head and neck cancer, Head Neck, 35, 1652, 10.1002/hed.23209 Holliday, 2016, Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: a case-matched control analysis, Med Dosim, 41, 189, 10.1016/j.meddos.2016.01.002 Blanchard, 2016, Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer – a case matched analysis, Radiother Oncol, 120, 48, 10.1016/j.radonc.2016.05.022 Blanchard, 2016, Toward a model-based patient selection strategy for proton therapy: external validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort, Radiother Oncol, 121, 381, 10.1016/j.radonc.2016.08.022 Weinstein, 2012, Transoral robotic surgery: a multicenter study to assess feasibility, safety, and surgical margins, Laryngoscope, 122, 1701, 10.1002/lary.23294 De Almeida, 2012, Robotic surgery for oropharynx cancer: promise, challenges and future directions, Curr Oncol Rep, 14, 148, 10.1007/s11912-012-0219-y Dowthwaite, 2012, The role of transoral robotic surgery in the management of oropharyngeal cancer: a review of the literature, ISRN Oncol, 2012 Ambrosch, 2001, Efficacy of selective neck dissection: a review of 503 cases of elective and therapeutic treatment of the neck in squamous cell carcinoma of the upper aerodigestive tract, Otolaryngol Head Neck Surg, 124, 180, 10.1067/mhn.2001.111598 Pellitteri, 1997, Expanded application of selective neck dissection with regard to nodal status, Head Neck, 19, 260, 10.1002/(SICI)1097-0347(199707)19:4<260::AID-HED3>3.0.CO;2-Z Sinha, 2012, Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma, Cancer, 118, 3519, 10.1002/cncr.26671 Brotherston, 2013, Patient preferences for oropharyngeal cancer treatment deescalation, Head Neck, 35, 151, 10.1002/hed.22930 Blanchard, 2016, Assessing head and neck cancer patient preferences and expectations: a systematic review, Oral Oncol, 62, 44, 10.1016/j.oraloncology.2016.09.008 Mirghani, 2014, Human papilloma virus testing in oropharyngeal squamous cell carcinoma: what the clinician should know, Oral Oncol, 50, 1, 10.1016/j.oraloncology.2013.10.008 Rietbergen, 2013, Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment de-escalation trials, Ann Oncol, 24, 2740, 10.1093/annonc/mdt319 Mirghani, 2015, Diagnosis of HPV-driven head and neck cancer with a single test in routine clinical practice, Mod Pathol, 28, 1518, 10.1038/modpathol.2015.113 Melotek, 2017, Optima: A phase II dose and volume de-escalation trial for high and low-risk HPV + oropharynx cancers, J Clin Oncol, 35, 6066, 10.1200/JCO.2017.35.15_suppl.6066